SCHEMBL29620769

SCHEMBL29620769

COc1ccc(-c2cn3cccnc3n2)cc1Cl

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.74
ALDH1A1 P00352 10/20 0.74
HPGD P15428 6/20 0.74
SMN1; SMN2 Q16637 5/20 0.74
GAA P10253 5/20 0.74
RAB9A P51151 5/20 0.74
GLA P06280 4/20 0.74
NPC1 O15118 4/20 0.74
MAPT P10636 4/20 0.74
POLB P06746 4/20 0.64
TP53 P04637 3/20 0.61
LMNA P02545 2/20 0.60
HSD17B10 Q99714 4/20 0.59
CYP1A2 P05177 1/20 0.59
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
THRB P10828 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23407644 1.00 KDM4E (0.74) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL10809568 0.88 KDM4E (0.79) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL29620819 0.85 KDM4E (1.00) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL15101458 0.85 KDM4E (0.74) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL23407628 0.85 KDM4E (1.00) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL6520447 0.82 KDM4E (0.70) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL23407691 0.82 KDM4E (0.82) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL10756169 0.82 KDM4E (0.67) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL12848878 0.81 KDM4E (0.62) KDM4EALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL24176656 0.80 ALDH1A1 (0.69) KDM4EALDH1A1HPGDSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3704105-B9 ANTIBACTERIAL COMPOUNDS DISCUVA LTD (GB) 2025-03-05 EP disclosed
EP-3704105-B1 ANTIBACTERIAL COMPOUNDS DISCUVA LTD (GB) 2024-10-16 EP disclosed
US-20220372027-A1 ANTIBACTERIAL COMPOUNDS DISCUVA LTD. (GB) 2022-11-24 US disclosed
US-11345694-B2 Antibacterial compounds DISCUVA LTD. (GB) 2022-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345694-B2 Antibacterial compounds CFTR, MRPL21, NQO1 KDM4E 4533/4885ALDH1A1 1908/4885HPGD 305/4885
US-20220372027-A1 ANTIBACTERIAL COMPOUNDS MRPL21, NRDC, PGLS KDM4E 3363/4885ALDH1A1 3982/4885HPGD 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.